PDS Biotechnology Corporation

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct immune responses against tumors, with programs spanning multiple oncology indications. The company also works on tumor-targeted approaches that combine immune activation with precision delivery, supporting research across head and neck, cervical, prostate, anal, breast, and other cancers. PDS Biotechnology Corporation operates as a specialist in immuno-oncology, aiming to address areas where conventional treatments may be limited. Based in Princeton, New Jersey, the company focuses on advancing current product candidates through clinical development and commercialization efforts in the biopharmaceutical market.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Frank K. Bedu-Addo Ph.D.

Employees

21

Headquarters

Princeton, NJ, United States

Website

www.pdsbiotech.com